Evidence map›Paper›PMID 40729004›Full record

ArticleCurrent issues in molecular biology2025

The Effects of Engeletin on Insulin Resistance Induced in Human HepG2 Liver Cells.

Erdem Toktay, Secil Nazife Parlak, Tugba Kavas, Harun Un, Rustem Anıl Ugan, Muhammed Yayla

Abstract read
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erdem ToktayDepartment of Histology and Embryology, Faculty of Medicine, Kafkas University, Kars 36000, Turkey.ORCID 0000-0002-0715-2707
Secil Nazife ParlakDepartment of Histology and Embryology, Faculty of Medicine, Agri Ibrahim Cecen University, Agri 04100, Turkey.
Tugba KavasDepartment of Medical Histology and Embryology, Faculty of Medicine, Kafkas University, Kars 36000, Turkey.ORCID 0000-0001-8410-8702
Harun UnDepartment of Biochemistry, Faculty of Pharmacy, Agri Ibrahim Cecen University, Agri 04100, Turkey.
Rustem Anıl UganDepartment of Pharmacology, Faculty of Pharmacy, Ataturk University, Erzurum 25000, Turkey.
Muhammed YaylaDepartment of Pharmacology, Faculty of Medicine, Selcuk University, Konya 42000, Turkey.ORCID 0000-0002-0659-3084

Funding

Kafkas University (2021-TS-52)
6 · The paper itself

Abstract

In this study, we aimed to investigate the effect of Engeletin (ENG) on insulin resistance and the associated oxidative cell damage in human HepG2 liver cells. The cells were grown in a cell culture medium, and insulin resistance was induced. After the determination of the toxic and effective doses of Engeletin, the effects of Engeletin on insulin resistance and insulin resistance-induced oxidative damage, inflammation, and apoptosis. To induce IR, culture plates were treated with 30 mM glucose and 50 nM insulin and incubated for 48 h. Engeletin and metformin were given one hour before starting the insulin resistance induction. In the HepG2 cells, insulin resistance decreased glucose consumption, the expression of ISR-1 and ISR-2, and the GLUT-2 levels, while they were all increased by Engeletin, which showed a metformin-like effect. In addition, Engeletin alleviated oxidative cell damage by decreasing MDA levels, which increased due to insulin resistance-induced oxidative stress, increasing the GSH and SOD levels and decreasing the caspase-3 (Cas-3), caspase-9 (Cas-9), and tumor necrosis factor alpha (TNF-α) levels, which also increase under insulin resistance conditions. Engeletin was found to have the protective and therapeutic effect of reducing insulin resistance (IR) and the oxidative cell damage it causes in human HepG2 cells.

Indexed as

EngeletinflavonoidsGLUT-2insulin resistanceISR-1ISR-2oxidative stress

Identifiers

PMID40729004
PMCPMC12293261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.